HRP20211261T8 - [1,2,4]triazolo[1,5-a]piridinil supstituirani spojevi indola - Google Patents
[1,2,4]triazolo[1,5-a]piridinil supstituirani spojevi indolaInfo
- Publication number
- HRP20211261T8 HRP20211261T8 HRP20211261TT HRP20211261T HRP20211261T8 HR P20211261 T8 HRP20211261 T8 HR P20211261T8 HR P20211261T T HRP20211261T T HR P20211261TT HR P20211261 T HRP20211261 T HR P20211261T HR P20211261 T8 HRP20211261 T8 HR P20211261T8
- Authority
- HR
- Croatia
- Prior art keywords
- triazolo
- substituted indole
- indole compounds
- pyridinyl substituted
- pyridinyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201611022328 | 2016-06-29 | ||
US15/635,055 US10071079B2 (en) | 2016-06-29 | 2017-06-27 | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds |
PCT/US2017/039633 WO2018005586A1 (en) | 2016-06-29 | 2017-06-28 | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds |
EP17737442.8A EP3478682B1 (en) | 2016-06-29 | 2017-06-28 | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
HRP20211261T1 HRP20211261T1 (hr) | 2021-11-26 |
HRP20211261T8 true HRP20211261T8 (hr) | 2022-01-21 |
Family
ID=60805851
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20211261TT HRP20211261T8 (hr) | 2016-06-29 | 2021-08-04 | [1,2,4]triazolo[1,5-a]piridinil supstituirani spojevi indola |
Country Status (31)
Country | Link |
---|---|
US (8) | US10071079B2 (hr) |
EP (1) | EP3478682B1 (hr) |
JP (1) | JP6995067B6 (hr) |
KR (1) | KR102473482B1 (hr) |
CN (1) | CN109641895B (hr) |
AR (1) | AR108905A1 (hr) |
AU (1) | AU2017287902B2 (hr) |
BR (1) | BR112018077119A2 (hr) |
CA (1) | CA3029620A1 (hr) |
CL (1) | CL2018003821A1 (hr) |
CO (1) | CO2019000686A2 (hr) |
CY (1) | CY1124514T1 (hr) |
DK (1) | DK3478682T3 (hr) |
EA (1) | EA037530B1 (hr) |
ES (1) | ES2886964T3 (hr) |
HR (1) | HRP20211261T8 (hr) |
HU (1) | HUE056091T2 (hr) |
IL (1) | IL263961B (hr) |
LT (1) | LT3478682T (hr) |
MX (1) | MX2018015422A (hr) |
MY (1) | MY196474A (hr) |
PE (1) | PE20190324A1 (hr) |
PL (1) | PL3478682T3 (hr) |
PT (1) | PT3478682T (hr) |
RS (1) | RS62292B1 (hr) |
SG (1) | SG11201811590RA (hr) |
SI (1) | SI3478682T1 (hr) |
TW (1) | TWI636053B (hr) |
UY (1) | UY37310A (hr) |
WO (1) | WO2018005586A1 (hr) |
ZA (1) | ZA201900571B (hr) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10071079B2 (en) | 2016-06-29 | 2018-09-11 | Bristol-Myers Squibb Company | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds |
EA038972B1 (ru) | 2016-07-30 | 2021-11-16 | Бристол-Маерс Сквибб Компани | Диметоксифенилзамещенные соединения индола в качестве ингибиторов tlr7, tlr8 или tlr9 |
KR102519535B1 (ko) | 2016-09-09 | 2023-04-06 | 브리스톨-마이어스 스큅 컴퍼니 | 피리딜 치환된 인돌 화합물 |
DK3526323T3 (da) | 2016-10-14 | 2023-06-26 | Prec Biosciences Inc | Modificerede meganucleaser der er specifikke for en genkendelsessekvens i hepatitis b virusgenomet |
CN110997656B (zh) | 2017-08-04 | 2023-04-14 | 百时美施贵宝公司 | 用作tlr7/8/9抑制剂的取代的吲哚化合物 |
KR20200036913A (ko) * | 2017-08-04 | 2020-04-07 | 브리스톨-마이어스 스큅 컴퍼니 | [1,2,4]트리아졸로[4,3-a]피리디닐 치환된 인돌 화합물 |
KR20200086709A (ko) * | 2017-11-14 | 2020-07-17 | 브리스톨-마이어스 스큅 컴퍼니 | 치환된 인돌 화합물 |
BR112020011668A2 (pt) * | 2017-12-15 | 2020-11-17 | Bristol-Myers Squibb Company | compostos de éter de indol substituído |
CA3085346A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Amide substituted indole compounds useful as tlr inhibitors |
KR20200101402A (ko) * | 2017-12-19 | 2020-08-27 | 브리스톨-마이어스 스큅 컴퍼니 | Tlr 억제제로서 유용한 치환된 인돌 화합물 |
CA3085761A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Triazole n-linked carbamoylcyclohexyl acids as lpa antagonists |
EP3728283B1 (en) | 2017-12-20 | 2023-11-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
AU2018392212B9 (en) | 2017-12-20 | 2021-03-18 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein |
CA3085942A1 (en) | 2017-12-20 | 2019-06-27 | Bristol-Myers Squibb Company | Aryl and heteroaryl substituted indole compounds |
BR112020011984A2 (pt) | 2017-12-20 | 2020-11-17 | Bristol-Myers Squibb Company | compostos de amino indol úteis como inibidores de tlr |
ES2904773T3 (es) * | 2017-12-20 | 2022-04-06 | Bristol Myers Squibb Co | Compuestos de diazaindol |
JP7328977B2 (ja) | 2018-02-12 | 2023-08-17 | エフ. ホフマン-ラ ロシュ アーゲー | ウイルス感染の処置および予防のための新規のスルホン化合物および誘導体 |
CN111788204B (zh) | 2018-02-26 | 2023-05-05 | 吉利德科学公司 | 作为hbv复制抑制剂的取代吡咯嗪化合物 |
US10870691B2 (en) | 2018-04-05 | 2020-12-22 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis B virus protein X |
TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | 2,2,─環二核苷酸 |
TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
TW201945388A (zh) | 2018-04-12 | 2019-12-01 | 美商精密生物科學公司 | 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶 |
WO2019211799A1 (en) | 2018-05-03 | 2019-11-07 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide |
TW202016105A (zh) | 2018-06-12 | 2020-05-01 | 瑞士商赫孚孟拉羅股份公司 | 用於治療自體免疫疾病的新穎雜芳基雜環基化合物 |
EP3807271A1 (en) * | 2018-06-13 | 2021-04-21 | F. Hoffmann-La Roche AG | Pyridinyl heterocyclyl compounds for the treatment of autoimmune disease |
WO2020020800A1 (en) | 2018-07-23 | 2020-01-30 | F. Hoffmann-La Roche Ag | Novel piperazine compounds for the treatment of autoimmune disease |
WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
US11639352B2 (en) | 2018-09-04 | 2023-05-02 | Hoffman-La Roche Inc. | Benzothiazole compounds for the treatment of autoimmune diseases |
JP2022502353A (ja) | 2018-09-06 | 2022-01-11 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 自己免疫疾患の処置のための新規の環状アミジン化合物 |
WO2020086505A1 (en) * | 2018-10-24 | 2020-04-30 | Bristol-Myers Squibb Company | Substituted indole dimer compounds |
JP2022505707A (ja) * | 2018-10-24 | 2022-01-14 | ブリストル-マイヤーズ スクイブ カンパニー | 置換インドールおよびインダゾール化合物 |
WO2020092528A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
JP7460644B2 (ja) | 2018-10-31 | 2024-04-02 | ギリアード サイエンシーズ, インコーポレイテッド | Hpk1阻害剤としての置換6-アザベンゾイミダゾール化合物 |
AU2020231115A1 (en) | 2019-03-07 | 2021-08-26 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
EP3935065A1 (en) | 2019-03-07 | 2022-01-12 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
EP3934757B1 (en) | 2019-03-07 | 2023-02-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 2'3'-cyclic dinucleotides and prodrugs thereof |
TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
TW202212339A (zh) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
US20220213099A1 (en) * | 2019-05-07 | 2022-07-07 | Bristol-Myers Squibb Company | Prodrug compounds |
TWI826690B (zh) | 2019-05-23 | 2023-12-21 | 美商基利科學股份有限公司 | 經取代之烯吲哚酮化物及其用途 |
CN110146631B (zh) * | 2019-06-25 | 2021-11-12 | 山西康宝生物制品股份有限公司 | 一种药用材料中聚乙二醇单甲醚残留量的检测方法 |
EP4017476A1 (en) | 2019-08-19 | 2022-06-29 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
CA3149557A1 (en) | 2019-09-30 | 2021-04-08 | Scott J. Balsitis | Hbv vaccines and methods treating hbv |
ES2965164T3 (es) * | 2019-10-04 | 2024-04-11 | Bristol Myers Squibb Co | Compuestos de carbazol sustituidos |
CN116057068A (zh) | 2019-12-06 | 2023-05-02 | 精密生物科学公司 | 对乙型肝炎病毒基因组中的识别序列具有特异性的优化的工程化大范围核酸酶 |
AU2021237718B2 (en) | 2020-03-20 | 2023-09-21 | Gilead Sciences, Inc. | Prodrugs of 4'-C-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
MX2022015760A (es) | 2020-06-11 | 2023-01-19 | Bristol Myers Squibb Co | Inhibidor del receptor tipo toll 7 (tlr7) en combinacion con prednisolona o hidroxicloroquina para el tratamiento del lupus eritematoso cutaneo. |
US20230310409A1 (en) | 2020-06-22 | 2023-10-05 | Bristol-Myers Squibb Company | Treating rheumatoid arthritis |
WO2022022489A1 (zh) * | 2020-07-27 | 2022-02-03 | 江苏恒瑞医药股份有限公司 | 吲哚稠环类衍生物、其制备方法及其在医药上的应用 |
MX2023006193A (es) | 2020-11-26 | 2023-06-09 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Compuesto triciclico fusionado, metodo de preparacion y aplicacion del mismo en medicina. |
IL307203A (en) | 2021-04-16 | 2023-11-01 | Gilead Sciences Inc | THIENOPYRROLE COMPOUNDS |
AU2022274607A1 (en) | 2021-05-13 | 2023-11-16 | Gilead Sciences, Inc. | COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS |
CN113416188B (zh) * | 2021-05-31 | 2022-12-13 | 河南偶联生物科技有限公司 | 一种[1,2,4]三唑并[1,5-a]吡啶化合物的合成方法 |
CA3222439A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2022271650A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
EP4359415A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
CN117480155A (zh) | 2021-06-23 | 2024-01-30 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
WO2024015825A1 (en) | 2022-07-13 | 2024-01-18 | Bristol-Myers Squibb Company | Processes for preparing 5-bromo-3,4-dimethylpyridin-2-amine and 6-bromo-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR9916363A (pt) | 1998-12-18 | 2001-12-11 | Axys Pharm Inc | Composto, composição farmacêutica e método paratratar ou prevenir um distúrbio tromboembólico |
BRPI0411514A (pt) | 2003-06-20 | 2006-08-01 | Coley Pharm Gmbh | antagonistas de receptor toll-like de molécula pequena |
WO2006113458A1 (en) * | 2005-04-15 | 2006-10-26 | Bristol-Myers Squibb Company | Heterocyclic inhibitors of protein arginine methyl transferases |
JP2009532501A (ja) | 2006-04-04 | 2009-09-10 | ミリアド ジェネティクス, インコーポレイテッド | 疾患および障害のための化合物 |
DE102006033109A1 (de) | 2006-07-18 | 2008-01-31 | Grünenthal GmbH | Substituierte Heteroaryl-Derivate |
US8027888B2 (en) | 2006-08-31 | 2011-09-27 | Experian Interactive Innovation Center, Llc | Online credit card prescreen systems and methods |
WO2008065198A1 (en) | 2006-12-01 | 2008-06-05 | Galapagos N.V. | Triazolopyridine compounds useful for the treatment of degenerative & inflammatory diseases |
WO2008152471A1 (en) | 2007-06-12 | 2008-12-18 | Coley Pharmaceutical Group, Inc. | Quinazoline derivative useful as toll-like receptor antagonist |
WO2009030996A1 (en) | 2007-09-05 | 2009-03-12 | Coley Pharmaceutical Group, Inc. | Triazole compounds as toll-like receptor (tlr) agonists |
FR2926556B1 (fr) | 2008-01-22 | 2010-02-19 | Sanofi Aventis | Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique |
WO2010036905A1 (en) | 2008-09-26 | 2010-04-01 | Eisai R & D Management Co., Ltd. | Benzoxazole compounds and methods of use |
US8785489B2 (en) | 2008-10-17 | 2014-07-22 | Boehringer Ingelheim International Gmbh | Heteroaryl substituted indole compounds useful as MMP-13 inhibitors |
KR20110132564A (ko) * | 2009-02-11 | 2011-12-08 | 선오비온 파마슈티컬스 인코포레이티드 | 히스타민 h3 역 작용제 및 길항제, 및 이의 사용 방법 |
SG176735A1 (en) * | 2009-06-10 | 2012-01-30 | Sunovion Pharmaceuticals Inc | Histamine h3 inverse agonists and antagonists and methods of use thereof |
TWI462920B (zh) | 2009-06-26 | 2014-12-01 | 葛萊伯格有限公司 | 用於治療退化性及發炎疾病之新穎化合物 |
PL2453895T3 (pl) | 2009-07-16 | 2018-10-31 | Mallinckrodt Llc | (+)-morfinany jako antagonisty receptora toll-like 9 i ich zastosowania terapeutyczne |
WO2012054862A2 (en) | 2010-10-21 | 2012-04-26 | The Brigham And Women's Hospital, Inc. | Agents, compositions, and methods for treating pruritis and related skin conditions |
US20140088085A1 (en) | 2011-01-12 | 2014-03-27 | Array Biopharma, Inc | Substituted Benzoazepines As Toll-Like Receptor Modulators |
CN106749023A (zh) | 2011-01-12 | 2017-05-31 | 帆德制药股份有限公司 | 作为toll样受体调节剂的取代的苯并氮杂卓 |
AU2012262014B2 (en) | 2011-06-01 | 2016-07-14 | Janus Biotherapeutics, Inc. | Novel immune system modulators |
EP2713737B1 (en) | 2011-06-01 | 2016-04-20 | Janus Biotherapeutics, Inc. | Novel immune system modulators |
EP2718279B1 (en) | 2011-06-09 | 2016-08-10 | Rhizen Pharmaceuticals SA | Novel compounds as modulators of gpr-119 |
CN103764655B (zh) * | 2011-07-13 | 2017-04-12 | Sk化学公司 | 作为alk5和/或alk4抑制剂的经2‑吡啶基取代的咪唑 |
WO2013052550A2 (en) | 2011-10-04 | 2013-04-11 | Janus Biotherapeutics, Inc. | Novel imidazole quinoline-based immune system modulators |
MY178053A (en) | 2012-05-18 | 2020-09-30 | Sumitomo Dainippon Pharma Co Ltd | Carboxylic acid compounds |
JO3407B1 (ar) | 2012-05-31 | 2019-10-20 | Eisai R&D Man Co Ltd | مركبات رباعي هيدرو بيرازولو بيريميدين |
SI3057964T1 (sl) | 2013-10-14 | 2020-03-31 | Eisai R&D Management Co., Ltd. | Selektivno substituirane spojine kinolina |
CA2933466A1 (en) | 2013-12-13 | 2015-06-18 | Takeda Pharmaceutical Company Limited | Pyrrolo[3,2-c]pyridine derivatives as tlr inhibitors |
US20170275287A1 (en) | 2014-08-22 | 2017-09-28 | Janus Biotherapeutics, Inc. | Novel n2, n4, n7, 6-tetrasubstituted pteridine-2,4,7-triamine and 2, 4, 6, 7-tetrasubstituted pteridine compounds and methods of synthesis and use thereof |
US9550778B2 (en) | 2014-10-03 | 2017-01-24 | Vanderbilt University | Substituted 6-aryl-imidazopyridine and 6-aryl-triazolopyridine carboxamide analogs as negative allosteric modulators of mGluR5 |
AU2016304899B2 (en) | 2015-08-13 | 2018-11-08 | Merck Sharp & Dohme Llc | Cyclic di-nucleotide compounds as sting agonists |
TN2018000452A1 (en) | 2016-06-29 | 2020-06-15 | Hanmi Pharm Ind Co Ltd | Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof |
MX2018016387A (es) | 2016-06-29 | 2019-09-09 | Kezar Life Sciences | Sales cristalinas de inhibidor de inmunoproteasoma de peptido epoxicetona. |
US10071079B2 (en) | 2016-06-29 | 2018-09-11 | Bristol-Myers Squibb Company | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds |
EA038972B1 (ru) | 2016-07-30 | 2021-11-16 | Бристол-Маерс Сквибб Компани | Диметоксифенилзамещенные соединения индола в качестве ингибиторов tlr7, tlr8 или tlr9 |
KR102519535B1 (ko) | 2016-09-09 | 2023-04-06 | 브리스톨-마이어스 스큅 컴퍼니 | 피리딜 치환된 인돌 화합물 |
CN110997656B (zh) | 2017-08-04 | 2023-04-14 | 百时美施贵宝公司 | 用作tlr7/8/9抑制剂的取代的吲哚化合物 |
KR20200036913A (ko) | 2017-08-04 | 2020-04-07 | 브리스톨-마이어스 스큅 컴퍼니 | [1,2,4]트리아졸로[4,3-a]피리디닐 치환된 인돌 화합물 |
KR20200086709A (ko) | 2017-11-14 | 2020-07-17 | 브리스톨-마이어스 스큅 컴퍼니 | 치환된 인돌 화합물 |
JP7289301B2 (ja) | 2017-12-18 | 2023-06-09 | ブリストル-マイヤーズ スクイブ カンパニー | 4-アザインドール化合物 |
KR20200101402A (ko) | 2017-12-19 | 2020-08-27 | 브리스톨-마이어스 스큅 컴퍼니 | Tlr 억제제로서 유용한 치환된 인돌 화합물 |
CA3085761A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Triazole n-linked carbamoylcyclohexyl acids as lpa antagonists |
CA3085346A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Amide substituted indole compounds useful as tlr inhibitors |
BR112020011984A2 (pt) | 2017-12-20 | 2020-11-17 | Bristol-Myers Squibb Company | compostos de amino indol úteis como inibidores de tlr |
CA3085942A1 (en) | 2017-12-20 | 2019-06-27 | Bristol-Myers Squibb Company | Aryl and heteroaryl substituted indole compounds |
ES2904773T3 (es) | 2017-12-20 | 2022-04-06 | Bristol Myers Squibb Co | Compuestos de diazaindol |
WO2020086505A1 (en) | 2018-10-24 | 2020-04-30 | Bristol-Myers Squibb Company | Substituted indole dimer compounds |
JP2022505707A (ja) | 2018-10-24 | 2022-01-14 | ブリストル-マイヤーズ スクイブ カンパニー | 置換インドールおよびインダゾール化合物 |
-
2017
- 2017-06-27 US US15/635,055 patent/US10071079B2/en not_active Ceased
- 2017-06-28 EA EA201990048A patent/EA037530B1/ru not_active IP Right Cessation
- 2017-06-28 SI SI201730890T patent/SI3478682T1/sl unknown
- 2017-06-28 PE PE2018003329A patent/PE20190324A1/es unknown
- 2017-06-28 AU AU2017287902A patent/AU2017287902B2/en active Active
- 2017-06-28 SG SG11201811590RA patent/SG11201811590RA/en unknown
- 2017-06-28 DK DK17737442.8T patent/DK3478682T3/da active
- 2017-06-28 HU HUE17737442A patent/HUE056091T2/hu unknown
- 2017-06-28 PL PL17737442T patent/PL3478682T3/pl unknown
- 2017-06-28 MY MYPI2018002975A patent/MY196474A/en unknown
- 2017-06-28 EP EP17737442.8A patent/EP3478682B1/en active Active
- 2017-06-28 LT LTEPPCT/US2017/039633T patent/LT3478682T/lt unknown
- 2017-06-28 JP JP2018568837A patent/JP6995067B6/ja active Active
- 2017-06-28 CA CA3029620A patent/CA3029620A1/en active Pending
- 2017-06-28 MX MX2018015422A patent/MX2018015422A/es active IP Right Grant
- 2017-06-28 AR ARP170101788A patent/AR108905A1/es unknown
- 2017-06-28 PT PT177374428T patent/PT3478682T/pt unknown
- 2017-06-28 TW TW106121570A patent/TWI636053B/zh active
- 2017-06-28 ES ES17737442T patent/ES2886964T3/es active Active
- 2017-06-28 BR BR112018077119-8A patent/BR112018077119A2/pt unknown
- 2017-06-28 KR KR1020197002353A patent/KR102473482B1/ko active IP Right Grant
- 2017-06-28 UY UY0001037310A patent/UY37310A/es unknown
- 2017-06-28 RS RS20211090A patent/RS62292B1/sr unknown
- 2017-06-28 WO PCT/US2017/039633 patent/WO2018005586A1/en unknown
- 2017-06-28 CN CN201780052726.1A patent/CN109641895B/zh active Active
-
2018
- 2018-07-23 US US16/042,116 patent/US10478424B2/en not_active Ceased
- 2018-12-25 IL IL263961A patent/IL263961B/en active IP Right Grant
- 2018-12-27 CL CL2018003821A patent/CL2018003821A1/es unknown
-
2019
- 2019-01-24 CO CONC2019/0000686A patent/CO2019000686A2/es unknown
- 2019-01-28 ZA ZA2019/00571A patent/ZA201900571B/en unknown
- 2019-10-15 US US16/653,297 patent/US10912766B2/en not_active Ceased
-
2020
- 2020-12-07 US US17/113,495 patent/US11672780B2/en active Active
-
2021
- 2021-08-04 HR HRP20211261TT patent/HRP20211261T8/hr unknown
- 2021-09-15 CY CY20211100814T patent/CY1124514T1/el unknown
-
2022
- 2022-01-25 US US17/584,147 patent/USRE49931E1/en active Active
- 2022-01-25 US US17/584,155 patent/USRE49893E1/en active Active
- 2022-01-25 US US17/584,139 patent/USRE49880E1/en active Active
-
2023
- 2023-04-26 US US18/307,119 patent/US20230255941A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20211261T8 (hr) | [1,2,4]triazolo[1,5-a]piridinil supstituirani spojevi indola | |
IL277576A (en) | Mutated pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | |
IL265918A (en) | Pyrazolo [1,5– A] compounds Pyridine is converted as RET kinase inhibitors | |
HK1258905A1 (zh) | 作為ret激酶抑制劑的取代的吡唑並[1,5-a]吡啶化合物 | |
HK1258157A1 (zh) | 作為jak抑制劑的吡唑並[1,5-a]吡嗪-4-基衍生物 | |
IL262673A (en) | A pyrazolo[5,1-a]pyrimidine compound | |
IL290419A (en) | Imidazo[a-1,5]pyrazine derivatives as inhibitors of pi3k delta |